The updated version of the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents has been updated to reflect the most recent prescribing information for lopinavir/ritonavir oral solution dosage. The dosage of 533 mg/133 mg is updated to 520 mg/130 mg in Table 20a. Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors and Appendix B, Table 3. Characteristics of Protease Inhibitors.